MDM2 and liposarcoma: [11] Moreover, in dedifferentiated liposarcoma, the TP53 pathway is downregulated by amplification and overexpression of its negative regulator MDM2. Consequently, a Phase III clinical trial on the use of MDM2 inhibitors (Brightline-1, NCT05218499) has been launched.